Scientists find a new layer of Alzheimer’s hidden in the genome
Recent scientific findings reveal a new layer of Alzheimer’s hidden within genome organization and broader cellular effects.
19 trends tracked about this subject — the full history, oldest to newest below.
Recent scientific findings reveal a new layer of Alzheimer’s hidden within genome organization and broader cellular effects.
Recent coverage highlights research connecting early detection of brain aging and Alzheimer's risk to gut health and specific microbes.
Recent coverage examines how nighttime awakenings may signal a connection to Alzheimer's disease risks.
Recent scientific research reveals that Alzheimer's disease threats may actually originate from beyond the brain.
Scientists have identified a new clue regarding the initial triggers of Alzheimer's-like brain damage, prompting a rethink of the disease's mechanisms.
Recent coverage highlights rising concerns over midlife dementia, stressing early evaluation and the risk of ignoring symptoms.
Recent research reveals that high-dose vitamin D supplementation may enhance cognitive function in populations vulnerable to dementia.
The US FDA has approved Lantheus and Enigma Biomedical's brain-imaging agent Tauklarify for Alzheimer's disease assessment.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage links a widely used supplement and common pill to faster Alzheimer's decline.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
14 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A new blood test is generating widespread attention for its reported ability to predict Alzheimer's disease symptoms years in advance.
Biogen defends its anti-tau drug following a stock decline triggered by a recent Alzheimer's treatment readout.
An experimental Alzheimer's drug shows early promise while raising mixed questions and triggering a stock drop.
Scientific research indicates early signs of dementia and Alzheimer's can appear up to 15 years prior to a formal clinical diagnosis.
New research identifies a link between long-term iron accumulation in the brain and the loss of neuronal resilience.